Company Filing History:
Years Active: 2022-2025
Title: Innovations by Inventor Peng Guo
Introduction
Peng Guo is a notable inventor based in Boston, MA, who has made significant contributions to the field of medical technology. He holds 2 patents that focus on innovative methods for detecting and treating cancer, particularly triple negative breast cancer (TNBC). His work is crucial in advancing therapeutic strategies that can improve patient outcomes.
Latest Patents
One of Peng Guo's latest patents is a method for detecting or treating triple negative breast cancer. This method involves the overexpression of ICAM-1, which is linked to an increased risk of TNBC. The patent describes a composition of matter that binds an anti-ICAM-1 antibody to a nanoparticle, which can be used as an imaging agent and/or a therapeutic targeting agent. Additionally, a therapeutically active molecule may be bound to this composition to provide targeted therapy.
Another significant patent by Guo involves engineered liposomes as cancer-targeted therapeutics. This disclosure provides cancer-targeting liposomes with ligands, such as EGFR ligands and ICAM-1 ligands, conjugated to the liposome surfaces. The molecular ratio of different ligands is designed to complement the relative molecular density of overexpressed proteins on the surface of targeted cancer cells.
Career Highlights
Peng Guo is currently associated with the Children's Medical Center Corporation, where he continues to innovate in the field of cancer research. His work is characterized by a strong focus on developing targeted therapies that can enhance the effectiveness of cancer treatments.
Collaborations
Throughout his career, Guo has collaborated with esteemed colleagues, including Marsha A Moses and Debra Auguste. These collaborations have further enriched his research and contributed to the advancement of medical technologies.
Conclusion
Peng Guo's innovative work in cancer detection and treatment exemplifies the impact of research and development in medical technology. His patents reflect a commitment to improving therapeutic strategies for challenging conditions like triple negative breast cancer.